Daily Derivative Report
SBI Securities
Retail Research
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
25 Feb 2025 | Nifty 50 |
SBI Securities
|
25019.80 |
Daily Note
|
|||||||
25 Feb 2025 | Nifty 50 |
SBI Securities
|
25019.80 |
Daily Note
|
|||||||
24 Feb 2025 | IPO |
Trendlyne Analysis
|
IPO Note
|
||||||||
24 Feb 2025 | Bank Nifty |
SBI Securities
|
55354.90 |
Daily Note
|
|||||||
24 Feb 2025 | World Economy and Markets |
Axis Direct
|
Daily Note
|
Daily Fundamental View:24 February 2025
Axis Direct
Asian markets are trading mixed, reflecting Wall Street's subdued session following lacklustre U.S. economic data that signalled a slowing economy and persistent inflation. Hang Seng is trading higher by 0.46%, while Shanghai Composite is marginally lower by 0.04%. Japanese markets remain closed.
|
|||||||
24 Feb 2025 | Nifty 50 |
SBI Securities
|
25019.80 |
Daily Note
|
|||||||
24 Feb 2025 | Nifty 50 |
SBI Securities
|
25019.80 |
Strategy Note
|
|||||||
21 Feb 2025 | Pharmaceuticals & Biotech. |
KRChoksey
|
Sector Update
|
Pharmaceuticals Sector Review
KRChoksey
In Q3FY25, companies within our pharma coverage revenue, EBITDA and Adj. PAT exceeded our expectations by 1.6%/3.7%/9.8%, respectively. The EBITDA margin and Adj. PAT margin outperformed our estimates by 53 bps and 133 bps, respectively.
|
|||||||
21 Feb 2025 | Bank Nifty |
SBI Securities
|
55354.90 |
Daily Note
|
|||||||
21 Feb 2025 | Retailing |
Axis Direct
|
Sector Update
|
||||||||
more
loading
|